Study of CNGB1 Retinitis Pigmentosa and Allied Hereditary Disorders

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision. Retinitis pigmentosa (RP) is a major cause of untreatable blindness associated with CNGB1 (CNGB1-RP). RP involves the death of photoreceptor cells that can be caused by mutations in a number of different genes. Treatment by gene therapy could prevent blindness in cases of inherited retinal dystrophies including RP. In the future RP due to mutations in CNGB1 may be treatable by gene therapy since this form of photoreceptor degeneration involves a slow loss of rod photoreceptor cells. This provides a wide window of opportunity for the identification of patients and initiation of treatment. Our efforts are directed toward developing gene therapy as a treatment. To this end, our objective is to better understand the disease process of CNGB1-RP and other allied inherited disorders so that we can develop clinical tests to measure the outcomes of treatment.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Diagnosis of CNGB1-associated RP by study physician, who are trained retinal specialists in the university clinic

• Must be able to commit to 4 follow-up study visits (3 years)

Locations
United States
New York
Dr. Stephen H. Tsang
RECRUITING
New York
Pennsylvania
Wills Eye Hospital
RECRUITING
Philadelphia
Other Locations
France
Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts
RECRUITING
Paris
Germany
Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich
RECRUITING
München
Eberhard Karls University Tubingen
RECRUITING
Tübingen
United Kingdom
Moorfields Eye Hospital NHS Foundation Trust
NOT_YET_RECRUITING
London
Contact Information
Primary
Amiela Canin
arc2282@cumc.columbia.edu
319-471-0920
Time Frame
Start Date: 2019-03-14
Estimated Completion Date: 2026-02
Participants
Target number of participants: 20
Sponsors
Collaborators: Ludwig-Maximilians - University of Munich, La Fondation Voir et Entendre, Michigan State University, Moorfields Eye Hospital NHS Foundation Trust, Universität Tübingen, Wills Eye
Leads: Columbia University

This content was sourced from clinicaltrials.gov